Ernexa Therapeutics announced progress on ERNA-101, a novel off-the-shelf cell therapy designed to convert immunologically "cold" tumors into immune targets, enhancing existing cancer immunotherapies. Preclinical studies showed complete tumor clearance and long-term survival in ovarian cancer models when combined with PD-1 blockade. The company is on track for its IND submission in Q3 2026 and plans a Phase 1 clinical trial in Q4 2026, initially focusing on platinum-resistant ovarian cancer. This approach aims to improve outcomes by combining therapies that attack tumors from multiple angles.
Crédit Agricole Normandie-Seine reported strong first-half 2026 results with record credit and deposit volumes, a 15.2 million euro increase in net banking income, and a 13.9% rise in net profit to 65.1 million euros. The bank's credit portfolio reac...
Virtual Investor Conferences announced that presentations from the July 22-23 Precious Metals & Critical Minerals Virtual Investor Conference are now available for on-demand viewing for 90 days. Investors can access company materials and schedule one...
EquipmentShare.com Inc. and some executives face a securities fraud lawsuit alleging they misled investors by not disclosing ongoing related-party transactions after their January 2026 IPO. The complaint claims founder-related entities continued undi...
BiomX's subsidiary Zorronet has partnered with Czech company Samura s.r.o. to expand its AI-powered monitoring technology across Central and Eastern Europe. The collaborations focus on smart pest management in agriculture and protecting critical tran...
The US federal debt exceeds $39 trillion, but foreign ownership of US Treasuries has dropped from nearly 49% in 2011-2012 to about 30-32% today. Traditional foreign buyers like China are reducing their holdings, while domestic investors and the Feder...
